Publicaciones en colaboración con investigadores/as de Hospital Universitario de Basurto (19)

2024

  1. Cancer risk with biologic and targeted synthetic DMARDs in patients with rheumatic diseases and previous malignancies: Results from the BIOBADASER register

    Seminars in Arthritis and Rheumatism, Vol. 64

  2. Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry

    Annals of the Rheumatic Diseases, Vol. 83, Núm. 9, pp. 1189-1199

2023

  1. Mucosal Immune Defence Gene Polymorphisms as Relevant Players in the Pathogenesis of IgA Vasculitis?

    International Journal of Molecular Sciences, Vol. 24, Núm. 17

2022

  1. Correction to: Real-World Effectiveness and Treatment Retention of Secukinumab in Patients with Psoriatic Arthritis and Axial Spondyloarthritis: A Descriptive Observational Analysis of the Spanish BIOBADASER Registry (Rheumatology and Therapy, (2022), 9, 4, (1031-1047), 10.1007/s40744-022-00446-9)

    Rheumatology and Therapy

  2. IgA Vasculitis: Influence of CD40, BLK and BANK1 Gene Polymorphisms

    Journal of Clinical Medicine, Vol. 11, Núm. 19

  3. Real-World Effectiveness and Treatment Retention of Secukinumab in Patients with Psoriatic Arthritis and Axial Spondyloarthritis: A Descriptive Observational Analysis of the Spanish BIOBADASER Registry

    Rheumatology and Therapy, Vol. 9, Núm. 4, pp. 1031-1047

2021

  1. Author Correction: BAFF, APRIL and BAFFR on the pathogenesis of Immunoglobulin-A vasculitis (Scientific Reports, (2021), 11, 1, (11510), 10.1038/s41598-021-91055-z)

    Scientific Reports

  2. BAFF, APRIL and BAFFR on the pathogenesis of Immunoglobulin-A vasculitis

    Scientific Reports, Vol. 11, Núm. 1

  3. Clinical factors associated with discontinuation of ts/bDMARDs in rheumatic patients from the BIOBADASER III registry

    Scientific Reports, Vol. 11, Núm. 1

  4. Role of the IL33 and IL1RL1 pathway in the pathogenesis of Immunoglobulin A vasculitis

    Scientific Reports, Vol. 11, Núm. 1

2020

  1. Influence of IL17A gene on the pathogenesis of immunoglobulin-A vasculitis

    Clinical and experimental rheumatology, Vol. 38, Núm. 2, pp. 166-170

  2. Influence of age on the occurrence of adverse events in rheumatic patients at the onset of biological treatment: Data from the BIOBADASER III register

    Arthritis Research and Therapy, Vol. 22, Núm. 1

  3. Role of IRF5 in the pathogenesis of immunoglobulin-A vasculitis

    Clinical and experimental rheumatology, Vol. 38, Núm. 2, pp. 182-187

2018

  1. Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients

    Seminars in Arthritis and Rheumatism, Vol. 48, Núm. 1, pp. 22-27

2017

  1. A genome-wide association study suggests the HLA Class II region as the major susceptibility locus for IgA vasculitis /692/699/1670 /692/4023/1670/595 article

    Scientific Reports, Vol. 7, Núm. 1

2015

  1. Association of HLA-B*41:02 with Henoch-Schönlein Purpura (IgA Vasculitis) in Spanish individuals irrespective of the HLA-DRB1 status

    Arthritis Research and Therapy, Vol. 17, Núm. 1

  2. Brief report: Association of HLA-DRB101 with IgA vasculitis (henoch-schönlein)

    Arthritis and Rheumatology, Vol. 67, Núm. 3, pp. 823-827

  3. Efficacy of anakinra in refractory adult-onset still's disease multicenter study of 41 patients and literature review

    Medicine (United States), Vol. 94, Núm. 39, pp. e1554

  4. Role of PTPN22 and CSK gene polymorphisms as predictors of susceptibility and clinical heterogeneity in patients with Henoch-Schönlein purpura (IgA vasculitis)

    Arthritis Research and Therapy, Vol. 17, Núm. 1